国际肝胆胰疾病杂志（英文版）2017，Vol.16Issue(5)：493-498,6.DOI:10.1016/S1499-3872(17)60009-2
Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma
Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma
Rong-Ce Zhao 1Jing Zhou 2Yong-Gang Wei 1Fei Liu 1Ke-Fei Chen 1Qiu Li 2Bo Li1
作者信息
- 1. Department of Liver Surgery and Liver Transplanta-tion CenterWest China Hospital, Sichuan University, Chengdu 610041, China
- 2. Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy,West China Hospital, Sichuan University, Chengdu 610041, China
- 折叠
摘要
关键词
hepatocellular carcinoma/transcatheter arterial chemoembolization/TACE in combination with sorafenib/cost-effectivenessKey words
hepatocellular carcinoma/transcatheter arterial chemoembolization/TACE in combination with sorafenib/cost-effectiveness引用本文复制引用
Rong-Ce Zhao,Jing Zhou,Yong-Gang Wei,Fei Liu,Ke-Fei Chen,Qiu Li,Bo Li..Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma[J].国际肝胆胰疾病杂志（英文版）,2017,16(5):493-498,6.
